Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Copyright 2023 – Finance News Network
Source: Finance News Network
26 Sep 2022 - European Metals Holdings Limited (ASX:EMH) discusses its Cinovec project, the largest hard rock lithium resource in Europe.
Read More02 Mar 2023 - Scott Kelly, RAM CEO Australia, provides an introduction to the RAM Essential Services Property Fund (ASX:REP), discussing geographical spread, yield, investment strategy, financials and inflation.
Read More13 Dec 2024 - Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that valuations remain high. He advises investors to adopt an active strategy, selecting individual growth-oriented stocks instead of relying on index funds.
Read More26 Aug 2024 - BluGlass Limited (ASX:BLG) CEO Jim Haden discusses the company's record quarter, IP deals, customer engagement and the upcoming Semiconductor Australia conference.
Read More03 Dec 2019 - Synertec Corporation Limited (ASX:SOP) Managing Director, Michael Carroll & CFO, David Harris talk FY19 results, market conditions and the outlook for specialist engineering and compliance services.
Read More18 Aug 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses the rationale for the sale of digital consultancy company Amblique, how the proceeds will be used, and the roadmap for the coming months.
Read More06 Mar 2024 - Arrow Minerals (ASX:AMD) Managing Director David Flanagan provides introduction to the company, discussing the companies Simandou North Iron Project in West Africa.
Read More10 Oct 2023 - Alex Hanly - CEO - Lithium Universe (ASX:LU7) objective is to construct a Lithium Project in Québec with utmost speed, and to assist Canada facilitate the transition towards cleaner energy.
Read More24 Feb 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the sectors to invest in given slowing global growth, tightening financial conditions, the risk of inflation and geopolitical imbalances.
Read More01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
Read More
